A
more ethical eye discomfort model to test the efficacy of your
compounds in reducing mild ocular pain
To propose ever more effective preclinical models, imitating better the aspects of the target pathology and allowing to study with increasing precision the target mechanisms of action, this is the motto of our research department.
Our team has recently developed and validated a new animal model that adds itself to our catalogue of animal models: formalin-induced ocular discomfort.
This model, more ethical than the severe pain models, allows studying the efficacy of your product in the treatment of ocular discomfort or mild pain in rabbits induced by instillation of formalin. Formalin is the common trade name for formaldehyde, which is a fixative that covalently cross-links proteins in a non-specific fashion.
Note that this model is being validated in rats as well.
Retinal degeneration: a new model of blue light-induced damage at Iris Pharma targeting the neuroprotection effect
This light damage model, developed and validated by our research department, allows testing the neuroprotector effect of your products in indications related to retinal degeneration and in particular the degeneration of photoreceptors as observed in retinopathy and dry AMD type pathologies.
This animal model is more ethical than the bright-light induced retinal degeneration model, as it reduces the light intensity and heat to which the animals are exposed as well as the duration of exposure with more satisfactory results.
See all our models
Surgical technique: our technicians have successfully performed partial vitrectomies in rabbits
Partial vitrectomy consists in removing part of the vitreous body (transparent gel filling the ocular cavity behind the crystalline lens). The technique we use in our laboratories consists in aspirating very slowly the vitreous body with a syringe and then re-injecting physiological fluid with another syringe in order to give the eyeball a normal volume.
It is a very delicate surgical technique, rarely used in animals, and most of the time performed in case of intra-vitreous haemorrhage that takes long to be resorbed, in case of retinal detachment or after certain ocular inflammations (for example uveitis). The consequences of the operation if it fails can be serious: detachment or rupture of the retina, lesion of crystalline lens and cataract.
More delicate than a standard vitrectomy, our technicians perform this operation in rabbits without provoking inflammation or causing any damage.
We congratulate them!
Iris Pharma CIR accreditation has been renewed
Attractive tax measures with Iris Pharma
For more than 6 years now, Iris Pharma has worked as an organization accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR). Our recognition procures a significant financial benefit – up to $10 million p.a. – for firms wishing to pursue their R & D work in ophthalmology with Iris Pharma.
CIR is a tax measure designed to support the R & D expenditures of firms located in France. It is calculated on the base of R & D expenditures – including those subcontracted to approved outside service providers.
The Ministry of Higher Education and Research delivers the accreditation based on the adequacy of an organization’s R & D potential. Iris Pharma can proudly point to the fact that we have been accredited this way since 2004, a token of the lasting performance of our activity.
New publications
SPATARO
G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C(a,b),
ELENA PP (d), MAJORAL JP (a,b), and CAMINADE AM (a,b). Designing
dendrimers for ocular delivery. Eur. J. Med. Chem. 2010; 45: 326-334.
AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), and CREAN C (b). Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation. J. Ocul. Pharmacol. Ther. 2009 Oct; 25: 433-439.
(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE Pharmaceuticals, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA
The purpose was to investigate the ocular distribution of 1% azithromycin ophthalmic solution and the effect of polycarbophil-based mucoadhesive formulation on ocular tissue levels of azithromycin after single and multiple topical administrations in the rabbit eye.
See more publications
To propose ever more effective preclinical models, imitating better the aspects of the target pathology and allowing to study with increasing precision the target mechanisms of action, this is the motto of our research department.
Our team has recently developed and validated a new animal model that adds itself to our catalogue of animal models: formalin-induced ocular discomfort.
This model, more ethical than the severe pain models, allows studying the efficacy of your product in the treatment of ocular discomfort or mild pain in rabbits induced by instillation of formalin. Formalin is the common trade name for formaldehyde, which is a fixative that covalently cross-links proteins in a non-specific fashion.
Note that this model is being validated in rats as well.
Retinal degeneration: a new model of blue light-induced damage at Iris Pharma targeting the neuroprotection effect
This light damage model, developed and validated by our research department, allows testing the neuroprotector effect of your products in indications related to retinal degeneration and in particular the degeneration of photoreceptors as observed in retinopathy and dry AMD type pathologies.
This animal model is more ethical than the bright-light induced retinal degeneration model, as it reduces the light intensity and heat to which the animals are exposed as well as the duration of exposure with more satisfactory results.
Light microscopy
photographs (magnification x400). Trichrome Masson staining of sagital
section of retina
 |
14 days after blue light exposure there were approximately four rows of photoreceptor nuclei remaining (ONL) and inner and outer segments were disrupted. |  |
See all our models
Surgical technique: our technicians have successfully performed partial vitrectomies in rabbits
Partial vitrectomy consists in removing part of the vitreous body (transparent gel filling the ocular cavity behind the crystalline lens). The technique we use in our laboratories consists in aspirating very slowly the vitreous body with a syringe and then re-injecting physiological fluid with another syringe in order to give the eyeball a normal volume.
It is a very delicate surgical technique, rarely used in animals, and most of the time performed in case of intra-vitreous haemorrhage that takes long to be resorbed, in case of retinal detachment or after certain ocular inflammations (for example uveitis). The consequences of the operation if it fails can be serious: detachment or rupture of the retina, lesion of crystalline lens and cataract.
More delicate than a standard vitrectomy, our technicians perform this operation in rabbits without provoking inflammation or causing any damage.
We congratulate them!
Iris Pharma CIR accreditation has been renewed
Attractive tax measures with Iris Pharma
For more than 6 years now, Iris Pharma has worked as an organization accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR). Our recognition procures a significant financial benefit – up to $10 million p.a. – for firms wishing to pursue their R & D work in ophthalmology with Iris Pharma.
CIR is a tax measure designed to support the R & D expenditures of firms located in France. It is calculated on the base of R & D expenditures – including those subcontracted to approved outside service providers.
The Ministry of Higher Education and Research delivers the accreditation based on the adequacy of an organization’s R & D potential. Iris Pharma can proudly point to the fact that we have been accredited this way since 2004, a token of the lasting performance of our activity.
New publications
SPATARO
G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C(a,b),
ELENA PP (d), MAJORAL JP (a,b), and CAMINADE AM (a,b). Designing
dendrimers for ocular delivery. Eur. J. Med. Chem. 2010; 45: 326-334.
(a)
CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b)
Universite de Toulouse, Toulouse, France - (c)
Hôpital
Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France.
New series of
phosphorus-containing dendrimers, having one quaternary
ammonium salt as core and carboxylic acid terminal groups have been
synthesized from generation 0 (3 carboxylic acid terminal groups) to
generation 2 (12 carboxylic acid terminal groups). These dendrimers
react with the neutral form of carteolol (an ocular anti-hypertensive
drug used to treat glaucoma) to afford ion pair (saline) species. The
solubility in water of these charged dendrimers depends on the
generation considered: generation 0 (3 carteolol) is well soluble,
whereas generation 1 (6 carteolol) and generation 2 (12 carteolol) are
poorly soluble. These dendrimers have been tested in vivo, as vehicle
for ocular drug delivery of carteolol to rabbits.
AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), and CREAN C (b). Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation. J. Ocul. Pharmacol. Ther. 2009 Oct; 25: 433-439.
(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE Pharmaceuticals, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA
The purpose was to investigate the ocular distribution of 1% azithromycin ophthalmic solution and the effect of polycarbophil-based mucoadhesive formulation on ocular tissue levels of azithromycin after single and multiple topical administrations in the rabbit eye.
See more publications
TOP
Upcoming events: where you can meet
with us
• March 11-13, 2010, Paris, France: Journées de Réflexions Ophtalmologiques (JRO)
• May 2-6, 2010, Fort Lauderdale, FL, USA: ARVO 2010, Booth # 400 - 402
• May 3-6, 2010, Chicago, USA: 2010 BIO International Convention
• March 11-13, 2010, Paris, France: Journées de Réflexions Ophtalmologiques (JRO)
• May 2-6, 2010, Fort Lauderdale, FL, USA: ARVO 2010, Booth # 400 - 402
• May 3-6, 2010, Chicago, USA: 2010 BIO International Convention
Iris
Pharma contributions: more than 40 ophthalmology drugs and devices
marketed
MORE THAN 40: the number of medicinal products and ophthalmic devices marketed and developed in which Iris Pharma participated actively in the last few years.
These medicinal products and devices concern the following pathologies and fields:
When you work with Iris Pharma, you benefit from the unique experience and background of an expert in ophthalmology. We supply the necessary understanding and experience to guide your new ophthalmic products through the development process in a rapid and cost-effective manner, allowing you to market your drugs and devices faster.
MORE THAN 40: the number of medicinal products and ophthalmic devices marketed and developed in which Iris Pharma participated actively in the last few years.
These medicinal products and devices concern the following pathologies and fields:
−
Glaucoma
− Dry eye
− Allergy
− Inflammation
− Infection (bacterial or viral)
− Ocular surgery
− Other fields (ophthalmic viscosurgical device or vasculo-protection)
− Dry eye
− Allergy
− Inflammation
− Infection (bacterial or viral)
− Ocular surgery
− Other fields (ophthalmic viscosurgical device or vasculo-protection)
When you work with Iris Pharma, you benefit from the unique experience and background of an expert in ophthalmology. We supply the necessary understanding and experience to guide your new ophthalmic products through the development process in a rapid and cost-effective manner, allowing you to market your drugs and devices faster.
Focus on clinical services
Clinical
assessment, in other words the testing of your new medicinal
products and devices in humans, both at a
toxicological or efficacy
level, is an essential step for the approval and marketing of your
product.
At Iris Pharma we
carry out phase
I, phase II-III
clinical trials and post
approval studies (phase IV and marketing
surveys) throughout
Western and Eastern Europe, North Africa, and North America.
Our experience at a glance
We have been a therapeutically specialised Contract Research Organisation focusing on ophthalmology clinical trials since 1994:
-
82
clinical trials performed
- 13 822 patients enrolled
- 2 172 clinical sites opened
- Some figures for 2009:
- 13 822 patients enrolled
- 2 172 clinical sites opened
- Some figures for 2009:
•
We have carried out more than a
hundred submissions
• We have recruited 1 144 patients…
• In 14 countries: Portugal, Spain, France, UK, Northern Ireland, Belgium, Holland, Italy, Austria, Switzerland, Germany, Denmark, Poland, Romania
• We have recruited 1 144 patients…
• In 14 countries: Portugal, Spain, France, UK, Northern Ireland, Belgium, Holland, Italy, Austria, Switzerland, Germany, Denmark, Poland, Romania
- An expertise in all clinical study phases
- All administration mode: topical, systemic, devices
We offer the overall development of a product for humans, from the feasibility of the study to the archiving of data: strategic consulting, strategic trial planning, regulatory requirements, clinical operations, scientific writing...
We
have developed key relationships and international experts networks
- A
well-established network of internationally renowned ophthalmologists
and investigative sites- Privileged contacts with international opinion leaders and experts in ophthalmology and pharmacology
- International network of local regulatory consultants
- Member of Regulatory and QA associations (EUCROF, CAQC, GCP news...)
For further information, please visit our website or contact us.
For more information on Iris Pharma activities, visit www.iris-pharma.com or contact us by email at info@iris-pharma.com.
If you no longer wish to receive the Iris Pharma Newsletter, please unsubscribe by email.